

02-04-09

Gp1651\$

ROGO-214.2-CONT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Asina, et al.
Serial No. : 09/735,073
Filed : December 12, 2000
For : COMPOSITION OF RESTRICTED CANCER CELLS
WHICH PRODUCE CANCER CELL PROLIFERATION
SUPPRESSIVE MATERIALS, AND USES THEREOF
Art Unit : 1651
Examiner : David M. Naff

February 3, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service by express mail EV 331558999 US in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA. 22313-1450 on the date shown below:

Eileen Sheffield

Signature

2/3/04
Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(RULE 1.97(d))

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The undersigned certifies that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart

02/09/2004 TBESHAH1 00000095 500624 09735073

01 FC:1806 180.00 DA

25379495.1

foreign application not more than three months prior to the filing of the information disclosure statement.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


Please charge the fee under Rule 1.17(p) to deposit account no 50-0624.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 
James R. Crawford
Reg. No. 39,155

666 Fifth Avenue
New York, New York 10103
(212) 318-3148
Enclosures



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/735,073
				Filing Date	12/12/2000
				First Named Inventor	Shirin Asina
				Art Unit	1651
				Examiner Name	David M. Naff
Sheet	1	of	1	Attorney Docket Number	ROGO-214.2-CONT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	MICHAEL S. O'REILLY, et al., Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma, Cell, Vol. 79, 315-328, October 21, 1994	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--